Eloxx Pharmaceuticals, Inc. (ELOX) stock
ELOXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$10.69+0.04 (+0.38%)
Close on Nov 20, 2026Market cap $72.58MP/E –Yield –
Eloxx Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Eloxx Pharmaceuticals's free cash flow for the twelve months ending Sep 30, 2023 was -$17.99M. For fiscal 2022 it was -$31.91M. The highest annual figure on record is -$3.68M in fiscal 2016.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -$31.91M | – |
| FY2021 | Dec 31, 2021 | -$35.09M | – |
| FY2019 | Dec 31, 2019 | -$39.43M | – |
| FY2018 | Dec 31, 2018 | -$31.60M | – |
| FY2016 | Jun 30, 2016 | -$3.68M | – |
| FY2015 | Jun 30, 2015 | -$7.47M | – |
| FY2014 | Jun 30, 2014 | -$4.87M | – |
| FY2013 | Jun 30, 2013 | -$3.90M | – |
| FY2012 | Jun 30, 2012 | -$4.39M | – |
| FY2011 | Jun 30, 2011 | -$5.39M | – |
| FY2010 | Jun 30, 2010 | -$4.74M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$3.45M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$2.07M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$6.81M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$5.66M | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$6.99M | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$9.75M | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$9.50M | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$9.95M | – |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$9.26M | – |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -$11.35M | – |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -$9.62M | – |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | -$9.20M | – |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | -$9.16M | – |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | -$8.13M | – |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | -$8.56M | – |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | -$5.75M | – |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | -$714.79K | – |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | -$840.98K | – |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | -$988.30K | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | -$1.13M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | -$2.43M | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | -$1.46M | – |
| Q2 FY2015CQ4 2014 | Dec 31, 2014 | -$1.57M | – |
| Q1 FY2015CQ3 2014 | Sep 30, 2014 | -$2.01M | – |
| Q4 FY2014CQ2 2014 | Jun 30, 2014 | -$1.22M | – |
| Q3 FY2014CQ1 2014 | Mar 31, 2014 | -$1.56M | – |
See a number that looks wrong?